These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30532996)

  • 1. Novel actions of sclerostin on bone.
    Holdsworth G; Roberts SJ; Ke HZ
    J Mol Endocrinol; 2019 Feb; 62(2):R167-R185. PubMed ID: 30532996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel insights on the effect of sclerostin on bone and other organs.
    Dreyer TJ; Keen JA; Wells LM; Roberts SJ
    J Endocrinol; 2023 May; 257(2):. PubMed ID: 36802398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones.
    Wang JS; Mazur CM; Wein MN
    Front Endocrinol (Lausanne); 2021; 12():584147. PubMed ID: 33776907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Sclerostin in Bone and Ectopic Calcification.
    Maré A; D'Haese PC; Verhulst A
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32366042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role and mechanism of action of sclerostin in bone.
    Delgado-Calle J; Sato AY; Bellido T
    Bone; 2017 Mar; 96():29-37. PubMed ID: 27742498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin: therapeutic horizons based upon its actions.
    Costa AG; Bilezikian JP
    Curr Osteoporos Rep; 2012 Mar; 10(1):64-72. PubMed ID: 22234741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin: from bench to bedside.
    Tanaka S; Matsumoto T
    J Bone Miner Metab; 2021 May; 39(3):332-340. PubMed ID: 33206222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin and its role as a bone modifying agent in periodontal disease.
    Ashifa N; Viswanathan K; Sundaram R; Srinivasan S
    J Oral Biosci; 2021 Jun; 63(2):104-110. PubMed ID: 33878470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin: recent advances and clinical implications.
    Honasoge M; Rao AD; Rao SD
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies.
    Chicana B; Donham C; Millan AJ; Manilay JO
    Curr Osteoporos Rep; 2019 Apr; 17(2):49-58. PubMed ID: 30835038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases.
    Boudin E; Fijalkowski I; Piters E; Van Hul W
    Semin Arthritis Rheum; 2013 Oct; 43(2):220-40. PubMed ID: 23433961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Regulation of Bone Metabolism and Disorders by Wnt Signaling.
    Maeda K; Kobayashi Y; Koide M; Uehara S; Okamoto M; Ishihara A; Kayama T; Saito M; Marumo K
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin and Vascular Pathophysiology.
    Catalano A; Bellone F; Morabito N; Corica F
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-sclerostin antibody : its bone formation effect and therapeutic potential for osteoporosis].
    Endo I
    Clin Calcium; 2014 Jan; 24(1):69-73. PubMed ID: 24369282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
    Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
    Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WNT-mediated Modulation of Bone Metabolism: Implications for WNT Targeting to Treat Extraskeletal Disorders.
    Bullock WA; Robling AG
    Toxicol Pathol; 2017 Oct; 45(7):864-868. PubMed ID: 29105581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application].
    Grebennikova TA; Belaya ZE; Rozhinskaya LY; Melnichenko GA
    Ter Arkh; 2016; 88(10):74-81. PubMed ID: 28635854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone.
    Salbach-Hirsch J; Samsonov SA; Hintze V; Hofbauer C; Picke AK; Rauner M; Gehrcke JP; Moeller S; Schnabelrauch M; Scharnweber D; Pisabarro MT; Hofbauer LC
    Biomaterials; 2015 Oct; 67():335-45. PubMed ID: 26232882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin and Bone Aging: A Mini-Review.
    Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
    Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.